Survival benefit associated with low-level physical activity.

1202 www.thelancet.com Vol 378 October 1, 2011 Survival benefi t associated with low-level physical activity 2 Prospective Studies Collaboration. Age-specifi c relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13. 3 Sever PS, Dahlöf B, Poulter NR, et al, for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–58. 4 Cholesterol Treatment Trialists’ (CTT) Collaborators. Effi cacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267–78. 5 Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011; 217 (suppl 1): 1–44. 6 Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58. 7 Yusuf S, Islam S, Chow CK, et al, on behalf of the Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011; published online Aug 28. DOI:10.1016/ S0140-6736(11)61302-0. 8 Heart Protection Study Collaborative Group. Cost-eff ectiveness of simvastatin in people at diff erent levels of vascular disease risk: economic analysis of a randomised trial in 20 536 individuals. Lancet 2005; 365: 1779–85.